PATH’s Drug Development program announces positive phase 1 results for its anti-diarrheal medication
Nov 15, 2012
Herald Online, November 2012
PATH’s Drug Development program announced today the completion of two phase 1 clinical studies for iOWH032—its investigational new drug to treat acute diarrhea caused by diseases such as cholera. Based on positive outcomes, iOWH032 will proceed into the next phase of clinical trials in Bangladesh in early 2013.